Bexson Biomedical
Tim Schlidt is a seasoned professional in the healthcare and finance sectors, currently serving as Co-Founder & Partner at Palo Santo since May 2020. Schlidt holds multiple board positions, including Board Member at Ksana Health and Board Observer roles at Gilgamesh Pharmaceuticals, Kanna Health, and Bexson Biomedical. Schlidt also provides advisory services to Tactogen and previously served as Board Member at Reset Pharmaceuticals. Prior experience includes a role as Private Equity Associate at Madison Dearborn Partners, LLC, and Investment Banking Analyst at Greenhill & Co., specializing in life sciences and healthcare services. Schlidt began a career in finance as an Investment Banking Summer Analyst at J.P. Morgan. Educational qualifications include a Bachelor of Business Administration in Finance, Investment & Banking from the University of Wisconsin-Madison.
This person is not in any teams
This person is not in any offices
Bexson Biomedical
2 followers
Bexson Biomedical is developing non-opioid therapies for pain management. Their goal is to provide therapies that provide relief to patients and reduce the rates of opioid addiction.